New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE ...

JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB).

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

Hundreds of children and adults in England with rare forms of cystic fibrosis will now be able to access a new triple-combinatio ...

Britain said it would strike an agreement with Vietnam to make it easier for pharmaceutical firms to sell UK-made medicines in the South-East Asian nation under a new trade strategy that emphasi­ses ...

The proposed recast of European pharmaceutical law includes novel requirements to combat medicines shortages. Medicines shortages are a hot topic ...

EU novel food authorizations typically take 2.5 years, and sometimes up to six. For many startups, that’s a death sentence.

From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.